Impact of Spinal Surgery on Intrathecal Nusinersen Injections in Pediatric Spinal Muscular Atrophy

被引:0
|
作者
Aksoy, Taha [1 ]
Ramazanov, Rafik [2 ]
Yildiz, Sibel Oz [3 ]
Demirkiran, Gokhan [1 ]
Haliloglu, Goknur [3 ]
Yazici, Muharrem [2 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Orthoped & Traumatol, Ankara, Turkiye
[2] Pediat Orthoped Spine Ctr, Cinnah Caddesi 112-2, TR-06690 Ankara, Turkiye
[3] Hacettepe Univ, Fac Med, Dept Pediat, Div Pediat Neurol, Ankara, Turkiye
关键词
spinal muscular atrophy; scoliosis; deformity; spinal surgery; nusinersen; intrathecal administration; injection; SHAM CONTROL;
D O I
10.1097/BPO.0000000000002703
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background:Complex spinal deformities necessitate surgical interventions that may intervene with intrathecal injections in patients with spinal muscular atrophy (SMA). This study aimed to determine the effect of spinal deformity correction surgery on nusinersen administration.Methods:Pediatric patients with SMA, operated by a single surgeon, either via magnetically controlled growing rod (MCGR) or definitive fusion (DF) with skip instrumentation, were evaluated retrospectively in terms of safety and feasibility of intrathecal injections. Patients' and their parents' perspectives were evaluated through a questionnaire regarding any shift in the setting of injections.Results:Fourteen patients with 15 spinal surgeries (10 MCGR and 5 DF) were included. Eleven patients received intrathecal treatment both before and after the surgery. Preoperative (n=3) and postoperative (n=9) fluoroscopic guidance was required leading to a shift in the application settings in 6 patients. Of 106 preoperative injections, 15% required fluoroscopy and 2% required anesthesia. Postoperatively, of 88 injections, 73% required fluoroscopy and 26% required anesthesia. No patients discontinued intrathecal injections due to technical difficulties associated with the spinal surgery.Conclusions:This study demonstrates that spinal surgery does not prevent safe and successful intrathecal nusinersen injections. In the DF group, the skip instrumentation technique provided access to interlaminal space for intrathecal injections. In either surgical group, no further auxillary approach was required. Modifications in the injection technique require an institutional approach, and concerns of patients and their families should be addressed accordingly.Level of Evidence:IV
引用
收藏
页码:e641 / e646
页数:6
相关论文
共 50 条
  • [41] Lumbar laminotomy for the intrathecal administration of nusinersen for spinal muscular atrophy: technical note and outcomes
    Ko, Diana
    Blatt, Daniel
    Karam, Chafic
    Gupta, Kunal
    Raslan, Ahmed M.
    JOURNAL OF NEUROSURGERY-SPINE, 2019, 31 (02) : 217 - 221
  • [42] Nusinersen and sleep in children with spinal muscular atrophy
    Saddi, V.
    Thambipillay, G.
    Farrar, M.
    Pithers, S.
    Williamson, B.
    Chuang, S.
    Teng, A.
    JOURNAL OF SLEEP RESEARCH, 2018, 27
  • [43] Impact Of Nusinersen Treatment On Measures Of Exercise Intolerance In Spinal Muscular Atrophy
    Uher, David
    Goodwin, Ashley M.
    De Vivo, Darryl C.
    Montes, Jacqueline
    Garber, Carol Ewing
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2023, 55 (09) : 964 - 964
  • [44] Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome
    Mirea, Andrada
    Leanca, Madalina Cristina
    Onose, Gelu
    Sporea, Corina
    Padure, Liliana
    Shelby, Elena-Silvia
    Dima, Vlad
    Daia, Cristina
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (06):
  • [45] Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience
    Ozutemiz, Can
    Karachunski, Peter
    Nascene, David R.
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2020, 26 (06) : 596 - 602
  • [46] Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy
    Schafernak, Kristian T.
    Jacobsen, Jeffrey R.
    Hernandez, Dulce
    Kaye, Robin D.
    Perez, Sylvia E.
    ACTA CYTOLOGICA, 2022, 66 (01) : 79 - 84
  • [47] Use of Ommaya Reservoir with a Thoracic Spinal Catheter for Intrathecal Delivery of Nusinersen in a Patient with Spinal Muscular Atrophy Type 2
    Lakhotia, Arpita
    Bhalla, Sonam
    Doll, Elizabeth
    Gump, Willam
    NEUROLOGY, 2018, 90
  • [48] A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy
    Zingariello, Carla D.
    Brandsema, John
    Drum, Elizabeth
    Henderson, Alicia A.
    Dubow, Scott
    Glanzman, Allan M.
    Mayer, Oscar
    Yum, Sabrina W.
    Kichula, Elizabeth A.
    NEUROLOGY-CLINICAL PRACTICE, 2019, 9 (05) : 424 - 432
  • [49] Multicenter Experience with Nusinersen Application via an Intrathecal Port and Catheter System in Spinal Muscular Atrophy
    Flotats-Bastardas, Marina
    Hahn, Andreas
    Schwartz, Oliver
    Linsler, Steffan
    Meyer, Sascha
    Kolodziej, Malgorzata
    Koehler, Cornelia
    NEUROPEDIATRICS, 2020, 51 (06) : 401 - 406
  • [50] Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy
    Carson, Vincent J.
    Young, Millie
    Brigatti, Karlla W.
    Robinson, Donna L.
    Reed, Robert M.
    Sohn, Jihee
    Petrillo, Marco
    Farwell, Wildon
    Miller, Freeman
    Strauss, Kevin A.
    MUSCLE & NERVE, 2022, 65 (01) : 51 - 59